Characterization of hepatitis B viral forms from patient plasma using velocity gradient: Evidence for an excess of capsids in fractions enriched in Dane particles.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
07
2022
accepted:
30
10
2022
entrez:
16
11
2022
pubmed:
17
11
2022
medline:
19
11
2022
Statut:
epublish
Résumé
Hepatitis B virus (HBV) morphogenesis is characterized by a large over-production of subviral particles and recently described new forms in parallel of complete viral particles (VP). This study was designed to depict circulating viral forms in HBV infected patient plasmas, using velocity gradients and most sensitive viral markers. Plasmas from chronic hepatitis B (CHB) patients, HBeAg positive or negative, genotype D or E, were fractionated on velocity and equilibrium gradients with or without detergent treatment. Antigenic and molecular markers were measured in plasma and in each collected fraction. Fast Nycodenz velocity gradients revealed good reproducibility and provided additional information to standard equilibrium sucrose gradients. HBV-RNAs circulated as enveloped particles in all plasmas, except one, and at lesser concentrations than VP. Calculations based on standardized measurements and relative virion and subviral particle molecular stoichiometry allowed to refine the experimental approach. For the HBeAg-positive plasma, VP were accompanied by an overproduction of enveloped capsids, either containing HBs, likely corresponding to empty virions, or for the main part, devoid of this viral envelope protein. Similarly, in the HBeAg-negative sample, HBs enveloped capsids, likely corresponding to empty virions, were detected and the presence of enveloped capsids devoid of HBs protein was suspected but not clearly evidenced due to the presence of contaminating high-density subviral particles. While HBeAg largely influences HBcrAg measurement and accounts for two-thirds of HBcrAg reactivity in HBeAg-positive patients, it remains a 10 times more sensitive marker than HBsAg to characterize VP containing fractions. Using Nycodenz velocity gradients and standardized biomarkers, our study proposes a detailed characterization of circulating viral forms in chronically HBV infected patients. We provide evidence for an excess of capsids in fractions enriched in Dane particles, likely due to the presence of empty virions but also by capsids enveloped by an HBs free lipid layer. Identification of this new circulating viral particle sets the basis for studies around the potential role of these entities in hepatitis B pathogeny and their physiological regulation.
Identifiants
pubmed: 36383523
doi: 10.1371/journal.pone.0272474
pii: PONE-D-22-20362
pmc: PMC9668129
doi:
Substances chimiques
Hepatitis B e Antigens
0
Iohexol
4419T9MX03
Hepatitis B Surface Antigens
0
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0272474Informations de copyright
Copyright: © 2022 Pronier et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Gastroenterology. 2002 Dec;123(6):1848-56
pubmed: 12454842
J Hepatol. 2020 Jul;73(1):40-51
pubmed: 32087349
J Clin Virol. 2022 Jun;150-151:105150
pubmed: 35427860
Hepatology. 2018 Dec;68(6):2106-2117
pubmed: 29734472
J Clin Microbiol. 2002 Feb;40(2):439-45
pubmed: 11825954
Nature. 2013 Apr 18;496(7445):367-71
pubmed: 23542590
J Gastroenterol. 2006 Aug;41(8):785-90
pubmed: 16988768
J Hepatol. 2016 Apr;64(1 Suppl):S4-S16
pubmed: 27084035
PLoS Pathog. 2018 May 21;14(5):e1007085
pubmed: 29782550
J Gen Virol. 2020 Jun;101(6):571-572
pubmed: 32416744
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
PLoS Pathog. 2011 Sep;7(9):e1002255
pubmed: 21966269
J Clin Microbiol. 2000 Aug;38(8):2897-901
pubmed: 10921947
J Virol. 2018 Jun 29;92(14):
pubmed: 29743374
J Hepatol. 2021 Aug;75(2):302-310
pubmed: 33762167
J Biol Chem. 2005 Jun 10;280(23):21713-9
pubmed: 15814524
J Viral Hepat. 2015 Sep;22(9):718-26
pubmed: 25644062
Cells. 2020 Sep 02;9(9):
pubmed: 32887393
Virol J. 2018 May 15;15(1):86
pubmed: 29764511
J Virol. 2015 Dec 30;90(7):3330-41
pubmed: 26719264
J Virol. 2021 Jan 13;95(3):
pubmed: 33148795
Hepatology. 2015 Jan;61(1):66-76
pubmed: 25132147
J Virol. 1984 Nov;52(2):396-402
pubmed: 6492255
J Hepatol. 2016 Oct;65(4):700-710
pubmed: 27245431
Antiviral Res. 2019 Sep;169:104553
pubmed: 31288041
J Hepatol. 2017 Dec;67(6):1281-1297
pubmed: 28736138
Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10205-10
pubmed: 17551004
J Viral Hepat. 2015 Jun;22(6):561-70
pubmed: 25395045
Clin Gastroenterol Hepatol. 2006 Jun;4(6):666-76
pubmed: 16765304
Hepatology. 2022 Nov;76(5):1520-1530
pubmed: 35342969